by Shannon Hayes | Feb 21, 2025 | Industry News and Updates, Top Stories
In a move that could shake up the medical spa industry, the FDA has officially resolved the shortages of Ozempic and Wegovy, signaling a potential crackdown on compounded semaglutide. This decision directly impacts medspas offering weight loss services, as many have...
by Medspa Mastery Desk | Dec 19, 2024 | Industry Insights, Industry News and Updates, Popular
December 19, 2024By Medspa Mastery News Team The FDA has officially declared the shortage of tirzepatide, the active ingredient in popular medications like Mounjaro and Zepbound, resolved. For months, compounding pharmacies filled the gap, providing off-label versions...
by Medspa Mastery Desk | Nov 1, 2024 | Industry News and Updates
Published on November 1, 2024 As medspas increasingly incorporate weight loss treatments into their offerings, tirzepatide has emerged as a notable option. However, the legal landscape surrounding the compounding of this medication is complex and evolving. This...
